According to a study unveiled by the European Medicines Agency (EMA) on Friday, the benefits of the AstraZeneca vaccine increase with age.
The body also confirmed the safety of the serum, despite concerns about rare cases of blood clots.
The European Medicines Agency (EMA) said on Friday after a new study that the benefits of the AstraZeneca Covid-19 vaccine increased with age and continued to outweigh the risks, such as cases of blood clots.
The European Commission had asked the EMA to conduct a new study following concerns from several European countries which have chosen to limit the use of the vaccine developed by the Anglo-Swedish laboratory AstraZeneca to the elderly because of reports of blood clots.
>> LIVE - Coronavirus: follow the evolution of the situation Friday April 23
Rare cases of blood clots
The study "showed that the benefits of vaccination increase with age," the European regulator said in a statement.
"The benefits of Vaxzevria (the name of the AstraZeneca vaccine) outweigh the risks in adults of all age groups," the EMA added.
AstraZeneca and Johnson & Johnson, two Covid-19 vaccines, based on the same technology, are suspected of causing a very rare type of blood clot.
The EMA recently announced that blood clots are expected to be listed as a "very rare" side effect of AstraZeneca and Johnson & Johnson vaccines against Covid-19.